In this task, you're given a paragraph and title from the research paper. Your task is to classify whether the given title is suitable or not for the research paper based on the given paragraph. Return "True" if title is proper according to paragraph else "False".

[EX Q]: Paragraph: Background: We undertook a 2X2 factorial, randomized controlled trial (RCT) to assess whether vitamin D 3 supplementation (10,000 international units per week) versus placebo and gargling versus no gargling could prevent viral, clinical upper respiratory tract infection (URTI) in university students. Methods: We randomized 600 students into 4 treatment arms: 1) vitamin D 3 and gargling, 2) placebo and gargling, 3) vitamin D 3 and no gargling, and 4) placebo and no gargling. Students completed weekly electronic surveys and submitted self-collected mid-turbinate nasal flocked swabs during September and October in 2010 or 2011. Symptomatic students also completed an electronic symptom diary. The primary and secondary outcomes were the occurrence of symptomatic clinical URTI and laboratory confirmed URTI respectively. Results: Of 600 participants, 471 (78.5%) completed all surveys while 43 (7.2%) completed none; 150 (25.0%) reported clinical URTI. Seventy participants (23.3%) randomized to vitamin D 3 reported clinical URTI compared to 80 (26.7%) randomized to placebo (RR:0.79, CI 95 :0.61-1.03, p = 0.09). Eighty-five participants (28.3%) randomized to gargling reported clinical URTI compared to 65 participants (21.7%) randomized to the no gargling arm (RR:1.3, CI 95 :0.92-1.57, p = 0.19). Laboratory testing identified 70 infections (46.7 per 100 URTIs). Vitamin D 3 treatment was associated with a significantly lower risk for laboratory confirmed URTI (RR: 0.54, CI 95 :0.34-0.84, p = 0.007) and with a significantly lower mean viral load measured as log 10 viral copies/mL (mean difference: −0.89, CI 95: -1.7, −0.06, p = 0.04). Fewer students assigned to gargling experienced laboratory confirmed URTI, however this was not statistically significant (RR:0.82, CI 95 :0.53-1.26, p = 0.36). Conclusions: These results suggest that vitamin D 3 is a promising intervention for the prevention of URTI. Vitamin D 3 significantly reduced the risk of laboratory confirmed URTI and may reduce the risk of clinical infections. Trial registration: Clinical Trials Registration: NCT01158560. 
 Title: Vitamin D 3 and gargling for the prevention of upper respiratory tract infections: a randomized controlled trial
[EX A]: True

[EX Q]: Paragraph: Brazzein protein comes from an edible fruit, which has a long history of being a staple in the local human diet in Africa. The attractive features of brazzein as a potential commercial sweetener include its small size (53 amino acid residues), its stability over wide ranges of temperature and pH, and the similarity of its sweetness to sucrose. Heterologous production of brazzein is complicated by the fact that the protein contains four disulfide bridges and requires a specific N-terminal sequence. Our previous protocol for producing the protein from Escherichia coli involved several steps with low overall yield: expression as a fusion protein, denaturation and renaturation, oxidation of the cysteines, and cleavage by cyanogen bromide at an engineered methionine adjacent to the desired N-terminus. The new protocol described here, which is much faster and leads to a higher yield of native protein, involves the production of brazzein in E. coli as a fusion with SUMO. The isolated protein product contains the brazzein domain folded with correct disulfide bonds formed and is then cleaved with a specific SUMO protease to liberate native brazzein. This protocol represents an important advancement that will enable more efficient research into the interaction between brazzein and the receptor as well as investigations to test the potential of brazzein as a commercially viable natural low calorie sweetener. 
 Title: Efficient and rapid protein expression and purification of small high disulfide containing sweet protein brazzein in E. coli
[EX A]: True

[EX Q]: Paragraph: The human metapneumovirus (hMPV) is a newly described member of the Paramyxoviridae family belonging to the Metapneumovirus genus. Since its initial description in 2001, hMPV has been reported in most parts of the world and isolated from the respiratory tract of subjects from all age groups. Despite the fact that prospective and case-control studies have been limited, the epidemiology and clinical manifestations associated with hMPV have been found to be reminiscent of those of the human respiratory syncytial virus, with most severe respiratory tract infections occurring in infants, elderly subjects, and immunocompromised hosts. Additional research is needed to define the pathogenesis of this viral infection and the host's specific immune response. Acute respiratory tract infections (ARTIs) are a major cause of morbidity and mortality worldwide. A variety of viruses, including the influenza viruses, human respiratory syncytial virus (hRSV), parainfluenza viruses, adenoviruses, rhinoviruses, and coronaviruses, have been associated with clinical syndromes ranging from mild illnesses, such as the common cold, to more severe devastating conditions, such as pneumonia. However, ∼50% of the cases of community-acquired pneumonia in adults and 15%-35% of cases of bronchiolitis and pneumonia in pediatric patients are still without a known etiology [1-3]. Along with inadequate diagnostic methods, this observation also suggests that other respiratory tract infectious agents may exist and remain to be identified. A new respiratory virus, the human metapneumovirus (hMPV) was first isolated in 2001 from nasopharyngeal aspirates (NPAs) obtained from young children in The Netherlands [4] . On the basis of morphological, biochemical, and genetic features, hMPV was tentatively classified with avian metapneumovirus (APV), the causative agent of an upper respiratory tract disease in turkeys and other birds [5], in the Metapneumovirus genus. The latter, together with the Pneumovirus genus (containing hRSV as the type species), is Note added in proof. Human metapneumovirus was recently isolated from previously virus-negative nasal wash specimens from 49 (20%) of 248 young children consulting at the Vanderbilt Clinic (Nashville, TN) for lower respiratory tract illnesses [44] . Extrapolation of these results to the entire cohort of patients observed at this institution over a 25-year period (1976-2001) suggests that the prevalence of human metapneumovirus infection was ∼12% in all outpatient children with lower respiratory tract diseases. 
 Title: Human Metapneumovirus: A New Player among Respiratory Viruses
[EX A]:
True